兔抗人MGMT单克隆抗体

实验原理
(1)特异性结合抗原:抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以清除病原微生物或导致病理损伤。然而，抗体可通过与病毒或毒素的特异性结合，直接发挥中和病毒的作用。(2)激活补体: loM、lgG1gG2和lgG3可通过经典途径激活补体，紧聚的IgA、lgG4和IE可通过替代途激活补体.(3) 结合细胞:不同类别的免疫球蛋白，可结合不同种的细胞，参与免疫应答.
(4)可通过胎盘及粘膜: 免疫球蛋白G (IgG) 能通过胎盘进入胎儿血流中，使胎儿形成自然被动免疫。免疫球蛋白A (lgA) 可通过消化道及呼吸道粘膜，是粘膜局部抗感染免疫的主要因素。(5)具有抗原性:抗体分子是一种蛋白质，也具有刺激机体产生免疫应答的性能。不同的免疫球蛋白分子，各具有不同的抗原性。
(6)抗体对理化因子的抵抗力与一般球蛋白相同:不耐热，60 ~ 70即被破坏。各种酶及能使蛋白质凝固变性的物质，均能破坏抗体的作用。抗体可被中性盐类沉淀。在生产上常可用疏酸被或硫酸钠从免疫血清中沉淀出含有抗体的球蛋白，再经透析法将其纯化。

产品附着到管壁或者瓶盖
1、液体状态：低速离心至管底即可使用。
2、干粉状态：4℃，12000rpm，3min。


抗体产品保存条件
1、-20℃保存，有效期1年。
2、荧光标记抗体请避光保存。
3、液态抗体产品中含有50%甘油，-20℃环境下仍为液态，有效避免了反复冻融对抗体品质的影响。

抗体稀释或溶解条件
非特殊定制产品或特殊实验条件亦可采用0.01M PBS（pH=7.2）对产品进行稀释或溶解。



产品个绍:
alpha-methylacyl-CoA racemase(AMACR/P504S) is Prostate-specific antigen (PSA) screening for prostatecancer is now widespread in the United States among men of all ages. However PSA has limited specificity becausebenign disease, including prostatic enlargement and inflammation, can increase PSA levels. Thus, a more specificprostate cancer markers is needed. One such potential marker is AMACR, an enzyme that is involved in peroxisomabeta-oxidation of dietary branched-chain fatty acids. Recent studies have shown that, compared with expression innormal or benign prostate epithelium, AMACR is consistently overexpressed in prostate cancer epithelium, making it aspecific marker for cancer cells within the prostate gland. Furthermore, overexpression of AMACR may increase the riskof prostate cancer because its expression is increased in premalignant lesions (prostatic intraepithelial neoplasia).
Function:
Racemization of 2-methy-branched fatty acid CoA esters. Responsible for the conversion of pristanoy-CoA and C27-bileacyl-CoAs to their (S)-stereoisomers.
Subcellular Location:
Peroxisome.Mitochondrion.
DISEASE:
Alpha-methylacyl-CoA racemase deficiency (AMACRD) MIM:614307): A rare autosomal recessive peroxisomal disordercharacterized by elevated plasma concentrations of pristanic acid C27-bile-acid intermediates,. and adult onset ofvariable neurodegenerative symptoms affecting the central and peripheral nervous systems. Features may includeseizures, visual failure, sensorimotor neuropathy, spasticity, migraine, and white matter hyperintensities on brainimaging. Note-The disease is caused by mutations affecting the gene represented in this entry.Congenital bile acid synthesis defect 4 (CBAS4) (MIM:2149501: A disorder characterized by the presence oftrihydroxycoprostanic acid in the bile and absence of cholic acid, Patients manifest neonatal jaundice, intrahepaticcho estasis and bile duct deficiency Note-The disease is caused by mutations affecting the gene represented in thisentry.